Nordea Investment Management AB Sells 1,600,906 Shares of IQVIA Holdings Inc. $IQV

Nordea Investment Management AB lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 69.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 713,313 shares of the medical research company’s stock after selling 1,600,906 shares during the quarter. Nordea Investment Management AB owned about 0.42% of IQVIA worth $161,508,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its stake in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in IQVIA during the third quarter valued at $30,000. Atlantic Union Bankshares Corp bought a new stake in IQVIA in the third quarter worth $36,000. Finally, Asset Dedication LLC grew its stake in shares of IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on IQV shares. Citigroup lowered their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, UBS Group cut their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Price Performance

Shares of NYSE:IQV opened at $165.91 on Monday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $28.16 billion, a price-to-earnings ratio of 21.11, a price-to-earnings-growth ratio of 1.60 and a beta of 1.40. The business has a 50-day simple moving average of $194.13 and a two-hundred day simple moving average of $206.19. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter last year, the firm posted $3.12 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.